Physician profile
Mohammad Alkhatib
NPI 1932436177
$3,250.65
in general payments reported to CMS, 2019-2025
26 companies · $792 in 2025
The $792 reported for 2025 was more than what 75% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.21 · 2020: $83.21 · 2021: $193 · 2022: $468 · 2023: $818 · 2024: $885 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,469.37 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $662.69 | 2020-2025 | Cabenuva, Rukobia, Dovato |
| Gilead Sciences, INC. | $423.33 | 2021-2025 | |
| Shionogi INC | $398.10 | 2022-2025 | Fetroja |
| Janssen Biotech, INC. | $370.50 | 2021-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $284.96 | 2021-2025 | Dificid, Zerbaxa, Recarbrio |
| Paratek Pharmaceuticals, INC. | $236.69 | 2022-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $173.32 | 2022-2025 | Xerava, Zevtera |
| Abbvie INC. | $95.79 | 2023-2024 | Avycaz, Dalvance |
| Emd Serono, INC. | $77.13 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $64.54 | 2019-2023 | Xarelto |
| Melinta Therapeutics, LLC | $64.10 | 2023-2024 | Rezzayo |
| Smith+Nephew, INC. | $56.75 | 2023-2025 | Grafix Pl, Collagenase Santyl |
| Insmed, INC. | $34.44 | 2024-2025 | Arikayce |
| Cumberland Pharmaceuticals, INC. | $33.83 | 2025 | Vibativ |
| Tactile Systems Technology INC | $31.76 | 2024 | Entre Plus, Flexitouch Plus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $25.58 | 2024 | Mytesi |
| Takeda Pharmaceuticals U.S.A., INC. | $24.20 | 2021 | |
| Nobel Biocare USA | $23.75 | 2023 | Nobelactive |
| Astrazeneca Pharmaceuticals Lp | $23.09 | 2022 | |
| Urgo Medical North America, LLC | $22.05 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Kerecis Limited | $21.97 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Aimmune Therapeutics, INC. | $21.75 | 2025 | Vowst |
| Koya Medical, INC. | $21.49 | 2025 | Koya Medical, Dayspring |
| Pfizer INC. | $19.71 | 2023 | |
| Mayne Pharma Commercial LLC | $19.63 | 2021 | |
| Ferring Pharmaceuticals INC. | $19.50 | 2025 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Alkhatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.